{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:26:57Z","timestamp":1760984817016},"reference-count":117,"publisher":"Elsevier BV","issue":"8","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.molmed.2013.06.003","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T00:19:53Z","timestamp":1372983593000},"page":"501-512","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Emerging treatments for pemphigoid diseases"],"prefix":"10.1016","volume":"19","author":[{"given":"Ralf J.","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Kalies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2013.06.003_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2013.06.003_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0015","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Mortality of bullous pemphigoid in Switzerland: a prospective study","volume":"165","author":"Cortes","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0025","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris \u2013 incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2013.06.003_bib0030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.molmed.2013.06.003_bib0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","article-title":"Epidermolysis bullosa acquisita","volume":"30","author":"Gupta","year":"2012","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clindermatol.2011.03.007","article-title":"Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)","volume":"30","author":"Chan","year":"2012","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJM198404193101602","article-title":"Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita","volume":"310","author":"Woodley","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/08916934.2011.606451","article-title":"Model systems duplicating epidermolysis bullosa acquisita: a methodological review","volume":"45","author":"Ludwig","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.molmed.2013.06.003_bib0055","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1073\/pnas.0809230106","article-title":"Anti-laminin \u03b3-1 pemphigoid","volume":"106","author":"Dainichi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2013.06.003_bib0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/1523-1747.ep12336033","article-title":"LAD-1 is absent in a subset of junctional epidermolysis bullosa patients","volume":"109","author":"Marinkovich","year":"1997","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/clim.2000.4845","article-title":"Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice","volume":"95","author":"Lazarova","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0070","doi-asserted-by":"crossref","first-page":"e41769","DOI":"10.1371\/journal.pone.0041769","article-title":"Pathogenicity of autoantibodies in anti-p200 pemphigoid","volume":"7","author":"Vafia","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2013.06.003_bib0075","first-page":"423","article-title":"Experimental animal models of bullous pemphigoid","volume":"144","author":"Heimbach","year":"2009","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916934.2011.606450","article-title":"Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen","volume":"45","author":"Chen","year":"2011","journal-title":"Autoimmunity"},{"key":"10.1016\/j.molmed.2013.06.003_bib0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1523-1747.ep12470317","article-title":"Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated","volume":"91","author":"Gammon","year":"1988","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0090","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1073\/pnas.93.16.8569","article-title":"A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid","volume":"93","author":"Delgado","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2013.06.003_bib0095","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1038\/jid.2011.231","article-title":"Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita","volume":"131","author":"Zumelzu","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jid.2010.248","article-title":"Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita","volume":"131","author":"Ludwig","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0105","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/jid.2011.466","article-title":"Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita","volume":"132","author":"Ludwig","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0110","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.4049\/jimmunol.0901412","article-title":"T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita","volume":"184","author":"Sitaru","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0115","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.4049\/jimmunol.0903101","article-title":"A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen","volume":"184","author":"Ujiie","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clim.2011.10.002","article-title":"Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model","volume":"142","author":"Ujiie","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0125","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal Fc receptor: from immunity to therapeutics","volume":"30","author":"Kuo","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0130","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00109-008-0366-7","article-title":"Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita","volume":"86","author":"Sesarman","year":"2008","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.molmed.2013.06.003_bib0140","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/path.2857","article-title":"Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita","volume":"224","author":"Ishii","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.det.2011.03.003","article-title":"Pathogenesis of epidermolysis bullosa acquisita","volume":"29","author":"Ludwig","year":"2011","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.molmed.2013.06.003_bib0155","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2005-08-3123","article-title":"Differential roles for \u03b22 integrins in experimental autoimmune bullous pemphigoid","volume":"107","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2013.06.003_bib0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0165","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.4049\/jimmunol.177.5.3398","article-title":"Role of FcRs in animal model of autoimmune bullous pemphigoid","volume":"177","author":"Zhao","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of Fc\u03b3RIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1172\/JCI3693","article-title":"A critical role for neutrophil elastase in experimental bullous pemphigoid","volume":"105","author":"Liu","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.1674","article-title":"Granulocyte-derived elastase and gelatinase B are required for dermal\u2013epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid","volume":"204","author":"Shimanovich","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2013.06.003_bib0190","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0195","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2013.06.003_bib0200","first-page":"1457","article-title":"A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis","volume":"25","author":"Wendling","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0205","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/ard.2003.013060","article-title":"Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation","volume":"63","author":"Nissler","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2013.06.003_bib0210","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.4049\/jimmunol.1100796","article-title":"Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice","volume":"187","author":"Hammers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0215","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1346-8138.2007.00375.x","article-title":"Efficacy of interferon-\u03b3 in patients with refractory bullous pemphigoid","volume":"34","author":"Nakama","year":"2007","journal-title":"J. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0220","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0225","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2013.06.003_bib0230","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1182\/blood-2010-10-314609","article-title":"Heat shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that non-malignant plasma cells are not therapeutic targets","volume":"117","author":"Kasperkiewicz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2013.06.003_bib0235","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.det.2011.03.008","article-title":"Pathogenesis of bullous pemphigoid","volume":"29","author":"Ujiie","year":"2011","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.molmed.2013.06.003_bib0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17460441.2011.563296","article-title":"Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment","volume":"6","author":"Patel","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.molmed.2013.06.003_bib0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1385\/IR:24:3:311","article-title":"CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes","volume":"24","author":"Bhushan","year":"2001","journal-title":"Immunol. Res."},{"key":"10.1016\/j.molmed.2013.06.003_bib0250","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2249.2009.03979.x","article-title":"Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders","volume":"157","author":"Levesque","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0255","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1003780","article-title":"Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model","volume":"187","author":"Patel","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0260","first-page":"251","article-title":"Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies","volume":"147","author":"Messingham","year":"2012","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0265","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/ni1306","article-title":"Particularities of the vasculature can promote the organ specificity of autoimmune attack","volume":"7","author":"Binstadt","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0270","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0275","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/1523-1747.ep12337492","article-title":"Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies","volume":"109","author":"Zillikens","year":"1997","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0280","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0285","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2353\/ajpath.2010.090744","article-title":"Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen","volume":"176","author":"Wang","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0290","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.1000667","article-title":"Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model","volume":"185","author":"Li","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0295","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaut.2012.04.002","article-title":"Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen","volume":"39","author":"Hirose","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2013.06.003_bib0300","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1744-9987.2005.00306.x","article-title":"Therapeutic apheresis \u2013 state of the art in the year 2005","volume":"9","author":"Bosch","year":"2005","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.molmed.2013.06.003_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jca.20268","article-title":"Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy","volume":"26","author":"Nagatomo","year":"2011","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.molmed.2013.06.003_bib0310","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg","year":"2012","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.molmed.2013.06.003_bib0315","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0320","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal\u2013epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0325","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0330","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.molmed.2013.06.003_bib0335","first-page":"529","article-title":"Drug evaluation: the C5a receptor antagonist PMX-53","volume":"8","author":"K\u00f6hl","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.molmed.2013.06.003_bib0340","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molimm.2009.08.032","article-title":"Recent developments in low molecular weight complement inhibitors","volume":"47","author":"Qu","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0345","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1074\/jbc.M310078200","article-title":"C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism","volume":"279","author":"Otto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2013.06.003_bib0350","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc\u03b3RIIB and dectin-1","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0355","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","article-title":"Successful treatment of mucous membrane pemphigoid with infliximab","volume":"142","author":"Heffernan","year":"2006","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0360","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.eye.6702948","article-title":"Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-\u03b1","volume":"21","author":"John","year":"2007","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.molmed.2013.06.003_bib0365","first-page":"68","article-title":"Recalcitrant cicatricial pemphigoid treated with the anti-TNF-\u03b1 agent etanercept","volume":"9","author":"Kennedy","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0370","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000318008","article-title":"Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports","volume":"221","author":"Boussemart","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.molmed.2013.06.003_bib0375","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0380","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2013.06.003_bib0385","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2012.08.002","article-title":"Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction","volume":"40","author":"Samavedam","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2013.06.003_bib0390","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid","volume":"108","author":"Chen","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0395","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2013.06.003_bib0400","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14728222.9.2.225","article-title":"Lymphocyte trafficking to inflamed skin \u2013 molecular mechanisms and implications for therapeutic target molecules","volume":"9","author":"Sch\u00f6n","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.molmed.2013.06.003_bib0405","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2013.06.003_bib0410","doi-asserted-by":"crossref","first-page":"23409","DOI":"10.1074\/jbc.R000004200","article-title":"The leukocyte integrins","volume":"275","author":"Harris","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2013.06.003_bib0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-065X.2009.00797.x","article-title":"PSGL-1 function in immunity and steady state homeostasis","volume":"230","author":"Carlow","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molmed.2013.06.003_bib0420","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood.V88.8.2973.bloodjournal8882973","article-title":"Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin","volume":"88","author":"Staite","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2013.06.003_bib0425","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1084\/jem.181.6.2259","article-title":"L-Selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites","volume":"181","author":"Tedder","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0430","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.192.11.1669","article-title":"P-Selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration","volume":"192","author":"Hirata","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0435","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/jid.2008.358","article-title":"PS3, a semisynthetic \u03b2-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions","volume":"129","author":"Alban","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0440","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.jid.5700504","article-title":"Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions","volume":"127","author":"Oostingh","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0445","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nm0402-366","article-title":"Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation","volume":"8","author":"Sch\u00f6n","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2013.06.003_bib0450","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0455","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/jid.2010.230","article-title":"Fc\u03b3RIIA and Fc\u03b3RIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous oemphigoid","volume":"30","author":"Yu","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0460","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00403-007-0755-8","article-title":"Relevance of the low-affinity type of the Fc\u03b3-receptor IIIa-polymorphism in bullous pemphigoid","volume":"299","author":"Weisenseel","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.molmed.2013.06.003_bib0465","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.4049\/jimmunol.155.10.4596","article-title":"Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases","volume":"155","author":"Johnson","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0470","doi-asserted-by":"crossref","first-page":"ra23","DOI":"10.1126\/scisignal.2001617","article-title":"Essential role for PI3K\u03b2 in neutrophil activation by immune complexes","volume":"4","author":"Kulkarni","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.molmed.2013.06.003_bib0475","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1515\/BC.1999.090","article-title":"Human Fc\u03b3 receptor IIb expressed in Escherichia coli reveals IgG binding capability","volume":"380","author":"Sondermann","year":"1999","journal-title":"Biol. Chem."},{"key":"10.1016\/j.molmed.2013.06.003_bib0480","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard.2006.068981","article-title":"Treatment of lupus-prone NZB\/NZW F1 mice with recombinant soluble Fc\u03b3 receptor II (CD32)","volume":"67","author":"Werwitzke","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2013.06.003_bib0485","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2008.02.002","article-title":"Amelioration of collagen-induced arthritis by human recombinant soluble Fc\u03b3RIIb","volume":"127","author":"Magnusson","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0490","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Coffey","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2013.06.003_bib0495","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2013.06.003_bib0500","doi-asserted-by":"crossref","DOI":"10.1038\/jid.2013.91","article-title":"Methylprednisolone blocks autoantibody-induced tissue damage through inhibition of neutrophil activation","author":"Hellberg","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10739680802350104","article-title":"Neutrophil adhesion and activation under flow","volume":"16","author":"Zarbock","year":"2009","journal-title":"Microcirculation"},{"key":"10.1016\/j.molmed.2013.06.003_bib0510","doi-asserted-by":"crossref","first-page":"823902","DOI":"10.1155\/2012\/823902","article-title":"Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease","volume":"2012","author":"Koppula","year":"2012","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.molmed.2013.06.003_bib0515","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01534392","article-title":"Antiinflammatory effects of NADPH oxidase inhibitors","volume":"19","author":"Miesel","year":"1995","journal-title":"Inflammation"},{"key":"10.1016\/j.molmed.2013.06.003_bib0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.matbio.2011.09.003","article-title":"Neutrophil elastase cleaves the murine hemidesmosomal protein BP180\/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid","volume":"31","author":"Lin","year":"2012","journal-title":"Matrix Biol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0525","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/path.2973","article-title":"Overexpression of the Flii gene increases dermal\u2013epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita","volume":"225","author":"Kopecki","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0530","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/jid.2012.457","article-title":"Topically applied flightless I neutralising antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita","volume":"133","author":"Kopecki","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0535","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000235974","article-title":"Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model","volume":"219","author":"Ren","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.molmed.2013.06.003_bib0540","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1189\/jlb.68.4.447","article-title":"The protective effect of IFN-\u03b3 in experimental autoimmune diseases: a central role of mycobacterial adjuvant-induced myelopoiesis","volume":"68","author":"Matthys","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0545","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1073\/pnas.0711271105","article-title":"IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions","volume":"105","author":"Collin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2013.06.003_bib0550","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2013.06.003_bib0555","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1165\/ajrcmb.22.5.3808","article-title":"Interleukin-6-induced protection in hyperoxic acute lung injury","volume":"22","author":"Ward","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0560","unstructured":"Fasano, A. et al. University of Maryland, Baltimore. Methods for screening for modulators of CXCR3 signaling, US 7622264"},{"key":"10.1016\/j.molmed.2013.06.003_bib0565","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/ATVBAHA.107.147827","article-title":"CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice","volume":"28","author":"van Wanrooij","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0570","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bcp.2006.05.006","article-title":"The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity","volume":"72","author":"Fritzsche","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.molmed.2013.06.003_bib0575","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1749-6632.2009.04739.x","article-title":"Sugar-free antibodies \u2013 the bacterial solution to autoimmunity?","volume":"1173","author":"Allhorn","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molmed.2013.06.003_bib0580","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4161\/mabs.19931","article-title":"Marketed therapeutic antibodies compendium","volume":"4","author":"Reichert","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.molmed.2013.06.003_bib0585","first-page":"339","article-title":"Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?","volume":"144","author":"Ludwig","year":"2009","journal-title":"G. Ital. Dermatol. Venereol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149141300110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149141300110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T22:26:15Z","timestamp":1688336775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149141300110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":117,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S147149141300110X"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2013.06.003","relation":{},"ISSN":["1471-4914"],"issn-type":[{"type":"print","value":"1471-4914"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging treatments for pemphigoid diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2013.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}